Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $255 | $219 | $234 | $1,069 |
| - Cash | $32 | $37 | $85 | $44 |
| + Debt | $201 | $226 | $222 | $27 |
| Enterprise Value | $424 | $408 | $371 | $1,051 |
| Revenue | $65 | $68 | $79 | $86 |
| % Growth | -3.4% | -14.6% | -8.1% | – |
| Gross Profit | $65 | $68 | $79 | $86 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$71 | -$105 | -$123 | -$119 |
| % Margin | -108.4% | -154.5% | -155.9% | -138.4% |
| Net Income | -$82 | -$116 | -$134 | -$122 |
| % Margin | -125.4% | -171.6% | -169% | -141.3% |
| EPS Diluted | -3.84 | -5.48 | -6.38 | -5.91 |
| % Growth | 29.9% | 14.1% | -8% | – |
| Operating Cash Flow | -$19 | -$79 | -$103 | -$85 |
| Capital Expenditures | -$13 | -$18 | -$9 | -$2 |
| Free Cash Flow | -$32 | -$97 | -$112 | -$87 |